medigraphic.com
ISSN 0016-3813 (Impreso)

2002, Número S1

<< Anterior Siguiente >>

Gac Med Mex 2002; 138 (S1)


Actualidades en linfomas y mieloma

I. Enfermedad de Hodgkin
II. Clasificación de linfomas (OMS): pasado, presente y futuro
III. Estado actual del tratamiento del linfoma maligno
IV. Tratamiento del mieloma múltiple
V. Avances recientes en mieloma múltiple

García-Vidrios V, Gutiérrez-Romero M, Rivas-Vera S, Sobrevilla-Calvo P, López-Karpovitch X

Idioma: Español
Referencias bibliográficas: 68
Paginas: 106-117
Archivo PDF: 82.48 Kb.


FRAGMENTO

Introducción

Linfoma de Hodgkin (LH)

El LH es una neoplasia del tejido linfoide caracterizada por la presencia de células malignas de Reed Sternberg en el sistema linfático, con características peculiares. Es la primera hemopatía maligna descrita, desde 1832, y también la primera que se consideró con posibilidades de curación, en la década de los sesenta, con los modernos esquemas de quimioterapia combinada. Desde el punto de vista epidemiológico, histopatológico y clínico, se comporta como una enfermedad heterogénea, con características diferentes a la mayoría de las enfermedades neoplásicas e incluso se ha cuestionado, si se trata de una sola entidad o de un conjunto de entidades de etiología y comportamiento diferente; no obstante, en la actualidad no hay duda del origen neoplásico de los LH, en base a la agresividad de su evolución y a la presencia de las células de Reed Sternberg, las cuales presentan aneuploidia y clonalidad variable. El International Lymphoma Study Group (clasificación REAL) y más recientemente la OMS, la incluyen por primera vez en una misma clasificación internacional junto con los linfomas no Hodgkin, dentro de la lista de las neoplasias linfoides, junto con otros procesos linfoproliferativos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Harris NL, Jaffe ES, Diebold J, Flandrin G, et al. The World Health Organization Classification of Hematological Malignancies Report, Clinical Advisors Committee Meeting, Airlie House, VA, USA, November 1997. Mod Pathol 2000;13(2):193-207.

  2. Stein H, Hummel M. Cellular origin and clonality of classic Hodgkin’s lymphoma: immunophenotype and molecular studies. Semin Hematol 1999;36(3):233.

  3. Advani RH,Horning SJ. Treatment of early-satge Hodgkin’s disease. Seminar in Hematology 1999:36(3):270.

  4. Engert A, Wolf J, Diehl V. Treatment of advanced Hodgkin’s lymphoma: standar and experimental approaches. Semin Hematol 1999:36(3):282.

  5. Ng AK, Mauch PM. Radiation therapy in Hodgkin’s lymphoma. Semin Hematol 1999:36(3):290.

  6. Laurence ADJ, Goldstone AH. High-dose therapy with hematopoietic transplantation for Hodgkin’s lymphoma. Semin Hematol 1999:36(3):303.

  7. The Non Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin’s Lymphom a: summary and description of a working formulation for clinical usage. Cancer 1982;49: 2112-35.

  8. Chan JCK, Banks PM, Cleary ML, et al. A Revised European-American Classification of Lymphoid Neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol 1995;103(5): 543-60.

  9. Harris NL. Lymphoma classification from controversy to consensus: the WHO Classification of Lymphoid Neoplasms. Ann Oncol 2000;11(1):3-10.

  10. Berard CW. The problem of classifying lymphomas: An orderly prescription for progress. Ann Oncol 1997;8(2):3-9. Group Classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood, 1997; 89:3090-18.

  11. Chan JCK. The New World Health Organization Classification of Lymphomas. The past, the present and the future. Hematol Oncol 2001;19:129-150.

  12. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987.

  13. Shipp MA. Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has “high-risk” disease?. Blood 1994;83:1165

  14. Bartologie B. Therapies in multiple myeloma. Semin Hematol 2001;38(3).

  15. Hudson MM, Donaldson SS. Hodgkin’s disease. Pediatr Clin North Am 1997;44:891-906.

  16. Gutiérrez RM, Gallardo TME. Enfermedad de Hodgkin. 4th ed. Medicine (III): 1993;552-529

  17. Tiehl V, von Kalle C, Fonatsch C, et al. The cell of origin in Hodgkin’s disease. Semin Oncol 1990;17:660.

  18. Bodis S, Kraus MD, Pinkus G, et al, Clinical presentation and outcome in lymphocyte- predominant Hodgkin’s disease. J Clin Oncol 1997;15:3060-6.

  19. Desser RK, Golomb HM, Ultman JE, et al. Prognostic classification of Hodgkin’s disease in pathologic stage III, based on anatomic considerations. Blood 1977;49:883.

  20. Cooper DL, De Vita VT. Hodgkin’s disease: current therapy and controversies. Adv Oncol 1994;10:17.

  21. Desch CE, Lasala MR, Smith TJ, et al. The optimal timing of autologous bone marrow transplantion in Hodgkin’s disease patients after chemotherapy relapse. J Clin Oncol 1992;10:200.

  22. Moskowitz CH, Zelentz AD, Trippett, et al. A 2-step comprehensive high-dose chemo-radiotherapy second-line program for relapsed and refractory Hodgkin’s disease: Analysis by intent to treat and development of a prognostic model. Blood 2001;97:16-23.

  23. Hiddemann W, Longo DL, Coiffuer B, Fisher RI, et al. Lymphoma classification- the gap between biology and clinical management is closing. Blood 1996;88(11):4085-89.

  24. Lukes RG, Collins RD. Immunological characterization of human malignant lymphomas. Cancer 1974; 34:1488-92.

  25. The Non Hodgkin’s Lymphoma Pathologic Classification Proyect: National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin’s Lymphom: summary and description of a working formulation for clinical usage. Cancer 1982;49: 2112-35.

  26. Chan JCK, Banks PM, Cleary ML, et al. A Revised European-American Classification of Lymphoid Neoplasms proposed by the International Lymphoma Study Group. A summary version. Am J Clin Pathol 1995;103(5): 543-60.

  27. Harris NL. Lymphoma classification from controversy to consensus: the WHO Classification of Lymphoid Neoplasms. Ann Oncol 2000;11(1):3-10.

  28. Harris NL, Jaffe ES, Diebold J, Flandrin G, et al. The World Health Organization Classification of Hematological Malignancies Report of the Clinical Advisors Committee Meeting, Airlic House, Virginia, November 1997. Mod Pathol 2000; 13(2):193-207.

  29. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues. A progress report. Am J Pathol 1999;111(1 Suppl 1): S8-12.

  30. Mason DY, Harris NL. Human lymphoma: clinical implications of the REAL Classification. London: Springer-Verlag Ltd.; 1999.

  31. Group Classification of Non-Hodgkin’s Lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997;89:309-18

  32. Berard CW. The problem of classifying lymphomas: An orderly prescription for progress. Ann Oncol 1997;8(2):3-9.Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997; 89:3090-18.

  33. Pileri SA, Milani M, Fraternali-Orcioni G, Sabattini E. From classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?

  34. Chan JCK. The New World Health Organization Classification of Lymphomas. The past, the present and the future. Hematol Oncol 2001;19:129-150.

  35. Beutz M, Trumper I. Workshop report: “Genetics and immunology of aggressive NHL”. Ann Hematol 2001;8(Suppl 3):B5-7.

  36. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, VA, USA. November, 1997. Ann Oncol 1999;10:1419-1432

  37. A predictive model for aggressive non-Hodgkin’s lymphoma: The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-994

  38. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med 1998;339: 21-26.

  39. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma N Engl J Med 1993;328:1002-1006.

  40. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s lymphoma. Blood 2000;95:3052-3056.

  41. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J Clin Oncol 2001;19:389-397.

  42. Coiffier B, Lepage E, Briere J, Herbrecht R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.

  43. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999;17:3793-3803.

  44. Press OW, Eary JF, Gooley T, Gopal AK, Stephen Liu, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000;96:2934-2942.

  45. Waters JS, Webb A, Cunningham C, Clarke PA, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin’s lymphoma. J Clin Oncol 2000;18:1812-1823.

  46. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99:1517-1526.

  47. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334.

  48. Myeloma Trialist’s Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma; an overview of 6,633 patientes from 27 randomized trials. J Clin Oncol 1998;16:3832.

  49. Attal M, Harousseau JL, Stoppa AM. A perspective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:9.

  50. Barlogie B, Jagannth S, Naucke S. Long-term follow-up after high dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998;21:1101.

  51. Desikan R, Barlogie B, Sawyer J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absense of chromosome 13 abnormalities. Blood 2000;95:4008.

  52. Attal M, Payen C, Facon T. Single versus double transplant in myeloma: a randomized trial of the “Inter Groupe Français du Myelome” (IFM). Blood 1997;90(Suppl 1):418a.

  53. Goldschmidt H, Cremer FW, Hegenbart U. Comparison of 3 high-dose regimens with autologous peripheral blood stem cell transplantation (TPX) for multiple myeloma (MM): a single center experience in 230 patients (PTS). Proc Soc Clin Oncol 1999;18:5a.

  54. Munshi NC, Barlogie B, Desikan KR. Novel approaches in myeloma therapy. Semin Oncol 1999;26:28.

  55. Gharton G, Svensson H, Cavo M. Progress in allogeneic bone marrow and peripheral bloodstem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-1993 and 1994-1998 at European Group for Blood and Marrow trasplantation Centres. Br J Haematol 2001;113:209.

  56. Lockhorst HM, Schattemberg a, Cornelissen JJ. Donor lymphocyte infusions for relapse multiple myeloma after allogeneic stem-cell trasnplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000;18:3031

  57. Giralt SA, Weber D, Alemán A. Nonmyeloablative conditioning with fludarabine/melphalan for patientes with multiple myeloma. Blood 1999;94(Suppl 1):1459a.

  58. Garban F, Attal M, Rossi JF. Immunotherapy by non-myeloablative allogeneis stem cell transplantation in multiplemyeloma: results of a pilot study as salvage therpy after autologous transplantation. Leukemia 2001;15:642.

  59. Davies FE, Raje N, Hideshima T. Thalidomide and immunomodulatory derivates augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98:210.

  60. Singhal S, Metha J, Desikan R. Antitumor actitivy of thalidomine in refractory multiple myeloma. N Engl J Med 1999;341:1565.

  61. Hideshima T, Richardson P, Chauhan D. The proteasome inhibitor PS-341 inhibits growth induces apoptosis, and overcomes drug resistence in human múltiple myeloma cells. Cancer Res 2001;61:3076.

  62. Tang B, Bajenova O, Feinman R. Arsenic compounds induce apoptosis in multiple myeloma (MM), activate pro-caspase-3 but do not affect BCL2 family members. Blood 1998;92(suppl1):638a.

  63. Park WH, Seol JG, Kim ES. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinasa inhibitos, P21 and apoptosis. Cancer Res 2000;60:3065.

  64. Munshi N. Arsenic trioxido: an emerging therapy for multiple myeloma. The Oncologist 2001;6(Suppl 2):17.

  65. Alberts B, Bray D, Lewis J, Raff H, Robert K, Watson JD. Cell growth and division. Molecular biology of the cell. 2nd ed.1989. p.727-790.

  66. Alberts B, Bray D, Lewis J, Raff H, Robert K, Watson JD. Cell growth and division. Molecular biology of the cell, 2nd ed. 1989. p. 1001-1057.

  67. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL. Multiple myeloma. Education Program. USA: American Society of Hematology; 2001. p. 157-177.

  68. Singhal S, Mehta J, Desikan R, et al. Anti tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 199;341:1566-1571.




2020     |     www.medigraphic.com